

Placenta growth factor inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/P95BC9649EBDEN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: P95BC9649EBDEN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Placenta Growth Factor Inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Placenta Growth Factor Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Placenta Growth Factor Inhibitors Understanding

Placenta Growth Factor Inhibitors: Overview

Placental Growth Factor (PIGF) is a pleiotropic cytokine, similar to vascular endothelial growth factor (VEGF), which binds to its membrane bound receptor—fms tyrosine kinase 1 (Flt-1) to stimulate angiogenesis.

Function - The placental growth factor (PGF) gene is a protein-coding gene and a member of the vascular endothelial growth factor (VEGF) family. The PGF gene is expressed only in human umbilical vein endothelial cells (HUVE) and the placenta. PGF is ultimately associated with angiogenesis. Specifically, PGF plays a role in trophoblast

growth and differentiation. Trophoblast cells, specifically extravillous trophoblast cells, are responsible for invading the uterine wall and the maternal spiral arteries. The extravillous trophoblast cells produce a blood vessel of larger diameter for the developing fetus that is independent of maternal vasoconstriction. This is essential for increased blood flow and reduced resistance.

Placenta Growth Factor Inhibitors - PlGF plays a significant role in experimental CNV. Increased levels of PlGF have also been reported in eyes of patients with diabetes and interference with its receptor during oxygen-induced ischemic retinopathy (OIR) inhibits neovascularization. Therefore, targeting PlGF may be a promising strategy for treatment of eye diseases with a neovascular component including diabetic retinopathy, retinopathy of prematurity and exudative AMD.

Placenta Growth Factor Inhibitors Emerging Drugs Chapters

This segment of the Placenta Growth Factor Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Placenta Growth Factor Inhibitors Emerging Drugs

FYB203: Bioeq

FYB203 is a biosimilar of aflibercept (Eylea®) which was licensed by Santo Holding from Formycon AG in May 2015. Similarly to Lucentis®, Eylea® is prescribed for the treatment of neovascular age-related macular degeneration (neovascular AMD) and other serious eye conditions. Currently, it is in phase 3 of development stage for the treatment of Wet age-related macular degeneration.

ABP 938: Amgen

ABP 938 (aflibercept), a biosimilar candidate to EYLEA, is a vascular endothelial growth factor receptor (VEGFR) Fc fusion protein. Currently, it is in phase 3 of development stage for the treatment of Wet age-related macular degeneration.

Further product details are provided in the report.....

Placenta Growth Factor Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Placenta Growth Factor Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Placenta Growth Factor Inhibitors

There are approx. 15+ key companies which are developing the Placenta Growth Factor Inhibitors. The companies which have their Placenta Growth Factor Inhibitors drug candidates in the most advanced stage, i.e. phase III include, Bioeq.

Phases

DelveInsight's report covers around 15+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Placenta Growth Factor Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Placenta Growth Factor Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Placenta Growth Factor Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Placenta Growth Factor Inhibitors drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Placenta Growth Factor Inhibitors R&D. The therapies under development are focused on novel approaches for Placenta Growth Factor Inhibitors.

Placenta Growth Factor Inhibitors Report Insights

Placenta Growth Factor Inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Placenta Growth Factor Inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Placenta Growth Factor Inhibitors drugs?

How many Placenta Growth Factor Inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Placenta Growth Factor Inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Placenta Growth Factor Inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Placenta Growth Factor Inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Regeneron

Ocular Therapeutix

Alteogen

4D Molecular Therapeutics

Celltrion

Amgen

Sam Chun Dang Pharm

Samsung Bioepis

Bioeq

Prestige Biopharma

Luye Pharma

GlycoNex

Momenta Pharmaceuticals

Alteogen

HEXAL

Bayer

Key Products

OTX-AFS

ALT L9

4D 150

CT-P42

ABP 938

SCD-411

SB-15

FYB203

PBP 1602

LY-09004

SEA Aflibercept Biosimilar

M-710

REGN 910-3

ALT L9

SOK583A1

BAY-865321

Contents

Introduction

Executive Summary

Placenta Growth Factor Inhibitors: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Placenta Growth Factor Inhibitors – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Placenta Growth Factor Inhibitors companies' collaborations, Licensing, Acquisition

-Deal Value Trends

Placenta Growth Factor Inhibitors Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

FYB203: Bioeq

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

REGN 910-3: Regeneron Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

ALT L9: Alteogen

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

4D 150: 4D MOLECULAR THERAPEUTICS

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Placenta Growth Factor Inhibitors Key Companies

Placenta Growth Factor Inhibitors Key Products

Placenta Growth Factor Inhibitors- Unmet Needs

Placenta Growth Factor Inhibitors- Market Drivers and Barriers

Placenta Growth Factor Inhibitors- Future Perspectives and Conclusion

Placenta Growth Factor Inhibitors Analyst Views

Placenta Growth Factor Inhibitors Key Companies

Appendix

I would like to order

Product name: Placenta growth factor inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/P95BC9649EBDEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P95BC9649EBDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970